Drug Profile
Dendritic cell-activated cytokine-induced killer cells - Shenzhen Hornetcorn Biotechnology
Alternative Names: Ag-D-CIK - Shenzhen Hornetcorn Biotechnology; Autologous dendritic cell cytokine-induced killer cell therapy - Shenzhen Hornetcorn; Autologous tumour lysate-pulsed DCIK - Shenzhen Hornetcorn; DC activated CIK - Shenzhen Hornetcorn Biotechnology; DC-CIK - Shenzhen Hornetcorn Biotechnology; DC-CIK Biotherapy - Shenzhen Hornetcorn Biotechnology; DCIK - Shenzhen Hornetcorn Biotechnology; Dendritic and cytokine-induced killer cells - Shenzhen Hornetcorn; Dendritic cell cytokine-induced killer cell therapy - Shenzhen HornetcornLatest Information Update: 07 Sep 2022
Price :
$50
*
At a glance
- Originator Shenzhen Hornetcorn Biotechnology
- Developer Affiliated Tumor Hospital of Guangzhou Medical University; Shenzhen Hornetcorn Biotechnology
- Class Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Cytokine-induced killer cell replacements; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Solid tumours
- Phase II Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 07 Sep 2022 Dendritic cell-activated cytokine-induced killer cells is still in phase-III trials for Solid tumours (Combination therapy, First-line therapy) in China (IV, infusion) (NCT04292769)
- 25 Jul 2022 Phase-III development in Solid tumours (Combination therapy, First-line therapy) is ongoing in China (IV) (NCT04292769)
- 21 Jan 2020 Phase-III clinical trials in Solid tumours (Combination therapy, First-line therapy) in China (IV) (NCT04292769)